Introduction
Multiple myeloma (MM) is characterized by the clonal proliferation of neoplastic plasma cells producing M-protein.
Although the use of allogeneic hematopoietic stem cell transplantation has been increasing, autologous stem cell transplantation (ASCT) remains the standard therapeutic modality for MM. [1] [2] [3] The main drawback of ASCT is its high relapse rate. Because immune-mediated tumor eradication may lower the relapse rate associated with ASCT, there is increasing interest in immune reconstitution following ASCT. [4] [5] [6] [7] [8] [9] In support of this, a relationship between lymphocyte recovery after ASCT and relapse rate or survival has been observed in many diseases, suggesting that early lymphocyte recovery associated with immune reconstitution can act against residual disease progression. [10] [11] [12] [13] [14] [15] [16] [17] Despite advances in treatment, MM is still an incurable disease. After ASCT had been proven to prolong diseasefree survival in MM patients, ASCT became an essential treatment modality for MM patients. Absolute lymphocyte count (ALC) on day þ 15 after ASCT has been reported to be an independent prognostic factor for MM, and the infused dose of autografted lymphocytes has been found to have a significant impact on clinical outcome after ASCT. 11, 15 These findings, however, were based on results using bone marrow (BM) and peripheral blood (PB) stem cells taking into consideration that most ASCTs are performed using PB as a hematopoietic stem cell source. Moreover, there are no confirmatory data to support the previous report. The survival of late lymphocyte recovery can be influenced by early treatment-related mortality (TRM) without full lymphocyte recovery. Therefore, the poorer survival in a group with late lymphocyte recovery can be misinterpreted when early TRM is incorporated. To evaluate the prognostic significance of ALC recovery after autologous PB stem cell transplantation (APBSCT), we have undertaken a retrospective analysis of patients with MM who underwent this procedure.
Materials and methods

Patients
From March 1993 to December 2003, 70 newly diagnosed MM patients underwent APBSCT at our institution. All patient data were collected prospectively and stored in a computerized database. Absolute lymphocyte count was reviewed retrospectively by retrieving computerized medical records. All patients were confirmed by national medical insurance organization to fit the guidelines for APBSCT. All patients gave written informed consent.
Inclusion criteria included age less than 70 years, Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 at the time of transplantation, life expectancy X8 weeks, and no evidence of serious organ dysfunction including renal, hepatic, cardiac, pulmonary, central nervous system and metabolic functions. Exclusion criteria included malignancies associated with human immunodeficiency virus or human T-cell lymphoma virus-1-associated malignancy, history of other malignant disease in the previous 5 years, except for squamous cell or basal cell carcinoma of the skin or stage I uterine cervical carcinoma or cervical carcinoma in situ or tandem APBSCT. We also excluded patients who died of TRM without engraftment.
Disease
Stage was originally classified by the Durie-Salmon staging system and reclassified by the international staging system. 18 The new staging system is focused on two common measures with prognostic importance in MM: serum b2-microglobulin (B2MG) and serum albumin concentrations. After three or more cycles of VAD (vincristine, adriamycin, dexamethasone) chemotherapy, all eligible MM patients underwent APBSCT.
Mobilization and collection of autologous hematopoietic stem cells
Mobilization regimens mainly consisted of cyclophosphamide. Hematopoietic growth factor (HPGF), also termed granulocyte-colony stimulating factor (10 mg/kg/day) was infused intravenously until completion of autologous hematopoietic stem cell collection. Mononuclear cells (MNCs) were collected using a blood cell separator CS-3000 s Plus (Baxtor, USA). At least 5 Â 10 6 CD34 þ cells/ kg were collected, but neither CD34-positive selection nor purging was applied.
Conditioning regimen
Conditioning consisted of melphalan (100 mg/m 2 ) for 2 days. Hematopoietic growth factor (filgrastim 300 mg/day) was given from day þ 1 until hematological engraftment, with the latter defined as the first day of absolute neutrophil count (ANC) X500/mm 3 for 3 consecutive days.
Absolute lymphocyte count and absolute lymphocyte count recovery days White blood cell (WBC) counts were performed using XE2100t (SYSMEX Co., Japan), and the percentage of lymphocytes was determined microscopically using the Wright stain. The ALC was calculated as the product of total WBC count and percentage of lymphocytes. Complete blood counts were measured every day until hematological engraftment, and the ALC was measured daily until it reached 500 cells/ml, after which it was measured until recovery to pretreatment values. Absolute lymphocyte count recovery days were calculated as described. 10 
Statistical analysis
The start date for all time variables was the day of APBSCT. The Kaplan-Meier method was used to assess overall survival (OS) and progression-free survival (PFS), and two-tailed log-rank tests were used to compare OS and PFS curves. Prognostic factors tested for MM were age; stage; performance; infused MNC dose and CD34 þ cells; total HPGF dose; ALC, ANC and platelet recovery days, and percentage of BM plasma cells; and serum concentrations of B2MG, hemoglobin, serum albumin and C-reactive protein (CRP). Factors with a P-value of less than 0.2 in univariate analysis were included in multivariate analysis, which was performed using the Cox regression hazard model. For quantitative variables, data are reported as medians (range) and means7standard errors. For qualitative variables, data are reported as number (percentage) of patients unless specified otherwise.
Results
Patient characteristics
A total of 70 newly diagnosed MM patients were enrolled in the study. We excluded patients who did not survive more than 30 days after APBSCT with full recovery of ANC. Of the 70 enrolled patients, three were ineligible owing to early death caused by TRM, without full lymphocyte recovery; and eight were ineligible due to double transplants. Thus, 59 patients, 32 (54.2%) males and 27 (45.8%) females, all of whom had a complete or partial response after APBSCT, were included in this study. 18 due to disease progression, three due to infection, one due to BM aplasia, one due to suicide and two due to other causes. Thirty-eight (64.4%) patients relapsed. The median time to progression was 11.0 months (range 2.0-37.5 months).
The group that recovered ALC X1000/mm 3 by day þ 23 after APBSCT had significantly higher median OS ( Figure 1 ) and prolonged PFS (Figure 2 ) than the group that did not (37.96 vs 23.19 months, P ¼ 0.0156; and 18.72 vs 9.11 months, P ¼ 0.0243, respectively). There were no differences in OS and PFS between groups stratified by time of recovery of ALC X500/mm 3 after APBSCT.
Univariate analysis
Univariate analysis showed that significant variables for OS included BM plasma cells p40% at diagnosis (P ¼ 0.0243) and recovery of ALC X1000/mm 3 by day þ 23 (P ¼ 0.0156). Bone marrow plasma cells p40% at diagnosis (P ¼ 0.0134) and recovery of ALC X1000/mm 3 by day þ 23 (P ¼ 0.0243, Table 2 ) were also positive predictors of PFS. Absolute neutrophil count X1000/mm 3 on day þ 12 was a marginally significant predictor of OS (P ¼ 0.0821) and PFS (P ¼ 0.1153).
When we tested days of recovery of ALC X100/mm 3 , ALC X300/mm 3 and ALC X500/mm 3 , we found that, over the range of 6-39 days, none of these correlated with OS or PFS. Only ALC X1000/mm 3 showed correlations with OS and PFS.
Multivariate analysis
Factors included in multivariate analysis included serum B2MG at diagnosis p5.5 mg/l, BM plasma cells p40% at diagnosis, recovery of ALC X1000/mm 3 by day þ 23 and recovery of ANC X1000/mm 3 by day þ 12 (Table 3) . We found that ALC X1000/mm 3 on day þ 23 was an independent prognostic factor for better OS (P ¼ 0.031; relative risk (RR) ¼ 4.810; 95% confidence interval (CI), 1.568-31.974) and for prolonged PFS (P ¼ 0.011; RR ¼ 7.081; 95% CI, 1.152-20.091). Bone marrow plasma cells at diagnosis was not an independent predictive factor for better OS (P ¼ 0.507, RR ¼ 1.445, 95% CI of RR 0.487-4.288) or PFS (P ¼ 0.103, RR ¼ 1.733, 95% CI of 
Discussion
Intensified chemotherapy with ASCT has been found to be superior to conventional therapy in the treatment of both younger and elder patients with MM, [19] [20] [21] and ASCT has become the standard therapy for newly diagnosed MM patients. In general practice, almost all patients with MM less than 65 years old undergo ASCT after initial chemotherapy such as VAD. Among the prognostic factors for ASCT, high concentrations of (B2MG), CRP and lactate dehydrogenase, and low concentrations of serum albumin have been associated with poorer outcome. 22, 23 The presence of chromosome 13 deletions and other chromosomal abnormalities is also associated with poorer survival. [24] [25] [26] [27] [28] Early ALC recovery after ASCT has been shown to be a prognostic factor for survival in patients with AML, breast cancer, Hodgkin's lymphoma, T/NK-cell lymphoma and primary systemic amyloidosis. 10, [12] [13] [14] 16 Similar findings have been reported in MM, 11 but, to date, no studies have confirmed the survival benefits of early ALC recovery after ASCT in MM. Our univariate analysis showed that early ALC recovery (X1000 cells/ml on day þ 23) following APBSCT and BM plasma cells p40% at diagnosis predicted longer PFS and OS in MM. In contrast, ANC recovery had marginal significance for OS and PFS. Multivariate analysis showed that only early ALC recovery was an independent prognostic factor for better OS and for prolonged PFS.
Our cut-off for ALC recovery, 1000 cells/ml by day þ 23, was chosen by calculating the median recovery day for ALC. We also verified the significance of this cut-off by testing other cut-off levels for ALC recovery, including 100, 300 and 500 cells/ml, all of which failed to show significance. Many studies of ALC recovery after SCT have utilized 500/ml as a cut-off value, and most of these analyzed all patients. However, we analyzed only those patients who survived more than 30 days after APBSCT with Table 3 Multivariate analysis for patients with multiple myeloma in relation to overall survival and progression-free survival full recovery of ANC. Moreover, ALC was considered recovered when it remained higher than 1000/ml for at least consecutive 3 days. Use of these strict criteria may show the importance of ALC recovery after APBSCT. How does early ALC recovery have a positive effect on survival after APBSCT? Immune reconstitution after HSCT is important not only for the restoration of normal protection against external hazards but also for the graftversus-tumor (GVT) effect. This effect has been shown in allogeneic HSCT, but not in APBSCT. Absolute lymphocyte count after allogeneic SCT has been found to correlate with acute or chronic graft-versus-host disease (GvHD). 29, 30 Minimal relapse with GvHD suggests that immune reconstitution may be important for the GVT effect. 31 Some studies of RIST for MM showed a possible graft-versus-myeloma effect, 1, 32 suggesting the immunemediated eradication of myeloma cells. That is, early immune reconstitution, represented by early ALC recovery, can suppress myeloma cells. Alternatively, ALC recovery may be a bystander for other effects. For example, dendritic cell recovery after ASCT can play a partial role in survival. 33 Absolute lymphocyte count has been found to be a consistent predictor of survival or relapse, irrespective of the exact mechanism of early lymphocyte recovery in many diseases after ASCT.
Recovery of lymphocyte subsets may help to define the precise role of early lymphocyte recovery. However, this retrospective data analysis limited further lymphocyte subset analysis. In this regard, all our suggestions are rather arbitrary. We are performing prospective observation for lymphocyte subset recovery after APBSCT. This will give us a hint as to the significance of ALC recovery. Autologous peripheral blood stem cell transplantation type such as a frontline therapy, after a relapse, or as a tandem transplantation also will affect the significance of ALC recovery. All patients who were analyzed in this study underwent APBSCT as a frontline therapy after induction VAD chemotherapy. The analysis of the early ALC recovery for eight double transplanted patients who were excluded in this study did not suggest any significance, in part owing to small number of patients (data not shown). Considering the wide use of tandem transplantation, ALC recovery after tandem transplantation should be examined.
Although infused ALC has been found to correlate with post transplant ALC recovery and survival, 15 there was no correlation between infused ALC and post transplant ALC recovery and survival. Many factors other than infused ALC may influence ALC recovery after ASCT. Our findings show that, in MM, early ALC recovery is a positive predictor of OS and PFS after APBSCT.
